As pharmaceutical tariffs on patented drug products and associated inputs approach a Sept. 29 implementation date, the Biotechnology Innovation Organization (BIO) said investor and company decision-making is being complicated by missing or unclear federal guidance, including exemptions. BIO noted potential reductions or exemptions tied to origin, temporary tariff relief through onshoring plans, and negotiated Most Favored Nation (MFN) pricing agreements. BIO warned that tariffs could reduce funding for treatment development and weaken patient access, even though generics and biosimilars face different exemption timelines. The guidance gap increases near-term uncertainty on total cost of goods and supply chain planning. For biopharma, the immediate focus is understanding which products and negotiation paths qualify for relief—and how compliance timelines affect procurement, pricing, and operational continuity.